# Sex Differences in Response to Viral Vector Vaccines—Implications for Future Vaccine Design

**Authors:** Ilka Grewe, Tamara Zoran, Marylyn Martina Addo

PMC · DOI: 10.1111/imr.70098 · 2026-01-30

## TL;DR

This review explores how males and females respond differently to viral vector vaccines and suggests that these differences should be considered in vaccine design.

## Contribution

The paper reviews sex-based differences in immune responses to viral vector vaccines and their implications for future vaccine development.

## Key findings

- Females generally show stronger immune responses to traditional vaccines compared to males.
- Sex differences in responses to viral vector vaccines are less studied but important for vaccine design.
- Understanding these differences can improve vaccine safety and efficacy for both sexes.

## Abstract

Vaccination represents one of the most impactful public health achievements, preventing 3.5 to 5 million deaths annually according to estimates of the World Health Organization. Yet, recent outbreaks of emerging and reemerging infectious diseases highlight the need for rapid and strategic vaccine development using vaccine platforms technologies. Sexual dimorphism in vaccine‐induced immune responses has received significant attention in recent years. To ensure vaccine safety and efficacy across sexes, sex‐based differences should be considered in vaccine design, dosing, and regimen. Evidence on many traditional vaccines, such as the inactivated influenza vaccine, shows a female bias in innate and adaptive immune responses following vaccination. Thus, it has long been suggested that females universally develop stronger humoral and cellular immune responses to vaccines compared to males. However, compared to traditional vaccines, studies investigating sex differences following vaccination with next‐generation platforms, such as viral vector vaccines, remain limited. This review provides an overview of clinical observations of sex differences in responses to replication‐competent and replication‐deficient, recombinant and nonrecombinant viral vaccines. Additionally, we describe the current state of knowledge on mechanisms of sex‐based differences in immune responses and possible implications for future vaccine design.

## Full-text entities

- **Genes:** GPER1 (G protein-coupled estrogen receptor 1) [NCBI Gene 2852] {aka CEPR, CMKRL2, DRY12, FEG-1, GPCR-Br, GPER}, LTA4H (leukotriene A4 hydrolase) [NCBI Gene 4048], IFNA1 (interferon alpha 1) [NCBI Gene 3439] {aka IFL, IFN, IFN-ALPHA, IFN-alphaD, IFNA13, IFNA@}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, VTN (vitronectin) [NCBI Gene 7448] {aka V75, VN, VNT}, S (surface glycoprotein) [NCBI Gene 43740568] {aka spike glycoprotein}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, IFNA8 (interferon alpha 8) [NCBI Gene 3445] {aka IFN-alphaB}, ESR2 (estrogen receptor 2) [NCBI Gene 2100] {aka ER-BETA, ESR-BETA, ESRB, ESTRB, Erb, NR3A2}, TLR7 (toll like receptor 7) [NCBI Gene 51284] {aka IMD74, SLEB17, TLR7-like}, AD5 (Alzheimer disease 5) [NCBI Gene 8081], RPS6KA3 (ribosomal protein S6 kinase A3) [NCBI Gene 6197] {aka CLS, HU-3, ISPK-1, MAPKAPK1B, MRX19, RSK}, HLA-C (major histocompatibility complex, class I, C) [NCBI Gene 3107] {aka D6S204, HLA-JY3, HLAC, HLC-C, MHC, PSORS1}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, IL13RA1 (interleukin 13 receptor subunit alpha 1) [NCBI Gene 3597] {aka CD213A1, CT19, IL-13Ra, NR4}, CXCR3 (C-X-C motif chemokine receptor 3) [NCBI Gene 2833] {aka CD182, CD183, CKR-L2, CMKAR3, GPR9, IP10-R}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, RNF130 (ring finger protein 130) [NCBI Gene 55819] {aka G1RP, G1RZFP, GOLIATH, GP}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, ESR1 (estrogen receptor 1) [NCBI Gene 2099] {aka ER, ESR, ESRA, ESTRR, Era, NR3A1}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576] {aka GCP-1, GCP1, IL8, LECT, LUCT, LYNAP}, BTK (Bruton tyrosine kinase) [NCBI Gene 695] {aka AGMX1, AT, ATK, BPK, IGHD3, IMD1}, CCL2 (C-C motif chemokine ligand 2) [NCBI Gene 6347] {aka GDCF-2, HC11, HSMCR30, MCAF, MCP-1, MCP1}, CYBB (cytochrome b-245 beta chain) [NCBI Gene 1536] {aka AMCBX2, CGD, CGDX, GP91-1, GP91-PHOX, GP91PHOX}
- **Diseases:** erythema (MESH:D004890), needlestick injury (MESH:D016602), infected (MESH:D007239), polio (MESH:D011051), Crimean-Congo Hemorrhagic Fever virus (MESH:D006479), autoimmune diseases (MESH:D001327), dengue infection (MESH:D003715), Guillain-Barre-like syndromes (MESH:D020275), myalgia (MESH:D063806), vomiting (MESH:D014839), autoimmune thrombosis syndrome (MESH:D013927), multiorgan failure (MESH:D051437), Ebola (MESH:D019142), viremia (MESH:D014766), infectious disease (MESH:D003141), arthralgia (MESH:D018771), hepatitis A and B (MESH:D006509), HIV-1 infection (MESH:D015658), fatigue (MESH:D005221), encephalitis (MESH:D004660), CMV (MESH:D003586), measles (MESH:D008457), measles, mumps, and rubella (MESH:D009107), myocarditis (MESH:D009205), rabies (MESH:D011818), yellow fever (MESH:D015004), MERS (MESH:D018352), COVID-19 (MESH:D000086382), respiratory, ocular, and gastrointestinal infections (MESH:D012141), influenza (MESH:D007251), nausea (MESH:D009325), abdominal pain (MESH:D015746), neurotropic disease (MESH:D004194), rubella (MESH:D012409), meningoencephalitis (MESH:D008590), deaths (MESH:D003643), fever (MESH:D005334), vaccinia (MESH:D014615), skin lesions (MESH:D012871), varicella (MESH:D002644), estrogen (MESH:D056828), myopericarditis (MESH:D010146), Smallpox (MESH:D012899), pruritus (MESH:D011537), inflammation (MESH:D007249), Sex Bias (MESH:D058533), VITT (MESH:D011697), Acute viscerotropic disease (MESH:D000208), estradiol deficiency (MESH:D007153)
- **Chemicals:** Lipid (MESH:D008055), LTB4 (MESH:D007975), ChAd (-), Estradiol (MESH:D004958), LTA4 (MESH:D017572), Testosterone (MESH:D013739), mpox (MESH:C051836), estrone (MESH:D004970), progesterone (MESH:D011374), LPS (MESH:D008070)
- **Species:** Yellow fever virus (no rank) [taxon 11089], Bundibugyo virus (no rank) [taxon 565995], Chimpanzee adenovirus (species) [taxon 310542], Human immunodeficiency virus 1 (no rank) [taxon 11676], Orthopoxvirus vaccinia (species) [taxon 10245], Variola virus (smallpox virus, no rank) [taxon 10255], Influenza A virus (no rank) [taxon 11320], Severe acute respiratory syndrome-related coronavirus (no rank) [taxon 694009], Marburg virus [taxon 186537], Measles morbillivirus (no rank) [taxon 11234], Gallus gallus (bantam, species) [taxon 9031], Pan troglodytes (chimpanzee, species) [taxon 9598], Human adenovirus 5 (no rank) [taxon 28285], Middle East respiratory syndrome-related coronavirus (no rank) [taxon 1335626], Leishmania (subgenus) [taxon 38568], Hepatovirus A (no rank) [taxon 12092], Mus musculus (house mouse, species) [taxon 10090], Dengue virus (no rank) [taxon 12637], Plasmodium falciparum (malaria parasite P. falciparum, species) [taxon 5833], Ebola virus [taxon 186536], Nipah virus [taxon 121791], Ebola virus (no rank) [taxon 1570291], Severe acute respiratory syndrome coronavirus 2 (no rank) [taxon 2697049], Japanese encephalitis virus (no rank) [taxon 11072], Lassa virus [taxon 11620], Human adenovirus sp. (species) [taxon 1907210], Macaca mulatta (rhesus macaque, species) [taxon 9544], Homo sapiens (human, species) [taxon 9606], Hepatitis B virus (no rank) [taxon 10407], West Nile virus (no rank) [taxon 11082], Zika virus (no rank) [taxon 64320]
- **Cell lines:** Ad26 — Mus musculus (Mouse), Transformed cell line (CVCL_6A85), Ad26-SARS-CoV-2 — Homo sapiens (Human), Febrile seizures, familial, 3A, Induced pluripotent stem cell (CVCL_A1XH), Vero — Chlorocebus sabaeus (Green monkey), Spontaneously immortalized cell line (CVCL_0059), T — Homo sapiens (Human), Esophageal squamous cell carcinoma, Cancer cell line (CVCL_3174)

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12856389/full.md

---
Source: https://tomesphere.com/paper/PMC12856389